Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 completion103d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →PST-611 →source: globaldata

Apr 30, 2026phase 1 completion103d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

Therapy area: Respiratory. Indication: Streptococcal Pneumonia

full page →pneumococcal (20-valent) vaccine →source: globaldata

Apr 30, 2026phase 1 initiation103d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

full page →VC-005 →source: globaldata

Apr 30, 2026phase 1 initiation103d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

full page →MK-6050 →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 2 completion103d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion103d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

full page →dupilumab →source: globaldata

Apr 30, 2026phase 2 completion103d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion103d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion103d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion103d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion103d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion103d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion103d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026